独家|赛诺菲四价流感病毒裂解疫苗恢复供应中国市场

Core Viewpoint - Sanofi has resumed the supply of its quadrivalent influenza virus split vaccine to the Chinese market for the 2025-2026 flu season after receiving approval from the National Medical Products Administration [1] Group 1: Product Development and Approval - Sanofi has optimized the immunogenicity and product stability assessment during the production process of the influenza vaccine for the upcoming flu season [1] - The original liquid trial production was completed in December 2024, followed by continuous research and testing, all of which confirmed stable efficacy [1] Group 2: Historical Context - Sanofi temporarily halted the supply and sale of its influenza vaccine in China due to efficacy issues on August 27 of the previous year [1]